Global Antipyretic Drug Market 2023-2030

Description

List of Tables

Title: Global Antipyretic Drug Market Size, Share & Trends Analysis Report by Type (Paracetamol, Ibuprofen, Aspirin, NSAID and Others), by Sales Type (Prescription and Over the Counter (OTC)), by Sales Channels (Hospital Pharmacies, Drug Store & Retail Pharmacies, Online Pharmacies, and Others) Forecast Period (2023-2030).

The global antipyretic drug market is anticipated to grow at a CAGR of 2.2% during the forecast period (2023-2030). An antipyretic is a pharmaceutical agent that reduces or eliminates a fever, usually induced by some source of inflammation. Antipyretics cause the hypothalamus to override a prostaglandin-induced increase in temperature. The effects of flu varies it places a substantial burden on the health of people in the US each year. Center for Disease Control and Prevention (CDC) have estimated that out of 41 million incidences of illness, flu was diagnosed to be around 9 million. Among these, approximately 140,000-710,000 hospitalizations, and 12,000-52,000 mortalities have been experiences annually between 2010 and 2020.

Thus, there is a considerable increase in the demand and development of drugs treating such flu across the globe. For instance in May 2022, Johnson & Johnson Korea released the first powder-type children's antipyretic painkiller Children's Tylenol powder 160 mg in Korea. Children's Tylenol powder which gives relief from various effects such as headache, neuralgia, muscle pain, sprain pain, menstrual pain, toothache, and joint pain, as well as fever and pain caused by a cold, so it can be widely used for fever and labor. Hence, the market players are also focusing on introducing new dosage types of Antipyretic Drug solutions which will further bolster the market growth.

Segmental Outlook

The global antipyretic drug market is segmented on type, sales type, and sales channels. Based on the type, the market is sub-segmented into Paracetamol, Ibuprofen, Aspirin, NSAID, and others. Based on the sales type, the market is sub-segmented into prescription and OTC. Further, on the basis of dosage form, the market is sub-segmented into Tablet, Syrup, Injection, and Paste. Based on sales channels, the market is sub-segmented into hospital pharmacies, drug store & retail pharmacies, online pharmacies, and others.

The Over the Counter (OTC) Sub-Segment Is Anticipated To Hold a Considerable Share of the Global Antipyretic Drug Market

Among the industry vertical, the Over the Counter (OTC) is expected to hold a considerable share of the global antipyretic drug market. The segmental growth is attributed to the easy availability of antipyretic drug without doctor's prescription. Owing to which major businesses of the pharmaceutical industry are focusing on investing in effective antipyretic drug solutions for their organizations. For instance, in August 2021, UK government approved combined paracetamol and ibuprofen medicine for general sale a medicine that contains 200mg of ibuprofen and 500mg of paracetamol per tablet. It will become available without any medical prescription for public.

Regional Outlook

The global Antipyretic Drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, due to maximum number of COVID-19 cases and deaths, thus, with a plethora of patients reporting fever as a common symptom- the sales of antipyretics rocketed in the year, and others.

The Asia-Pacific Region is expected to grow at a Significant CAGR in the Global Antipyretic Drug Market

Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing geriatric population with other forms of chronic and viral illnesses. More than half of the cases of typhoid fever globally were projected to have occurred in India, the implementation of public vaccination has remained low, due to the lack of data regarding the contemporary disease burden.

Market Players Outlook

The major companies serving the Antipyretic Drug market include: Sun Pharmaceuticals Industries Ltd., Pfizer Inc., Johnson and Johnson (J&J), Glenmark Pharmaceuticals, Cipla Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, the Food and Drug Administration (FDA) expanded the approval of Caldolor (ibuprofen injection) to include infants 3 to 6 months of age for the treatment of pain and fever. Previously, the treatment was approved for patients 6 months of age and older.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global antipyretic drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027476

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Sun pharmaceuticals Industries Ltd.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Johnson and Johnson (J&J)
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Pfizer Inc.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Antipyretic Drug Market By Type
- 4.1.1. Paracetamol
- 4.1.2. Ibuprofen
- 4.1.3. Non-Steroidal Anti-Inflammatory Drugs (NSAID)
- 4.1.4. Others
4.2. Global Antipyretic Drug Market by Sales Type
- 4.2.1. Prescription (Rx)
- 4.2.2. Over the Counter (OTC)
4.3. Global Antipyretic Drug Market by Sales Channel
- 4.3.1. Hospital Pharmacies
- 4.3.2. Drug Store & Retail Pharmacies
- 4.3.3. Online Pharmacies
- 4.3.4. Others (Supermarkets)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. BASF SE
6.2. CIPLA Ltd
6.3. Cumberland Pharmaceuticals
6.4. Divi's Laboratories Limited
6.5. Dr. Reddy's Laboratories
6.6. Elfin Drugs Private Limited
6.7. Glenmark Pharmaceuticals
6.8. GSK Pharmaceuticals
6.9. Jordanian Pharmaceutical Manufacturing
6.10. LUPIN Limited
6.11. Novartis AG
6.12. NPS MedicineWise
6.13. Strides Pharma
6.14. Torrent Pharmaceuticals Ltd
6.15. ZYDUS Life